News Releases

Date Title and Summary
Toggle Summary electroCore Announces New Patent for Stroke and TIA Treatment
ROCKAWAY, NJ , Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
Toggle Summary electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices
ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods
Toggle Summary electroCore Announces Listing Transfer to the Nasdaq Capital Market
ROCKAWAY, N.J. , June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq
Toggle Summary electroCore Announces Issuance of Two New U.S. Patents
ROCKAWAY, N.J. , Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS)
Toggle Summary electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones
ROCKAWAY, NJ , July 27, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile
Toggle Summary electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J. , May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024 , Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and
Toggle Summary electroCore Announces gammaCore(TM) Listing on the NHS Supply Chain Catalogue
LONDON , and BASKING RIDGE, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc.  (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore TM , the company’s non-invasive vagus nerve stimulator (nVNS), will appear on the NHS Supply
Toggle Summary electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke
ROCKAWAY, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.
Toggle Summary electroCore Announces Frank R. Amato to Step Down as Chief Executive Officer
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
Toggle Summary electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
Record full year 2023  net sales of $ 16.0 million increased 87%  over $8 .6  million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J. , March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc.